Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1). They found that a closely related compound will activate an enzyme, AMPK, triggering a cellular 'recycling' system that helps reduce elevated cholesterol and other accumulated fats in the brains and livers of NPC1 patients, which are hallmarks associated with severe neurological problems.
The US Preventive Services Task Force recommends that primary care professionals individualize the decision to offer or refer adults without obesity who do not have high blood pressure, abnormal cholesterol or blood sugar levels or diabetes to behavioral counseling to promote a healthful diet and physical activity. Existing evidence indicates a positive but small benefit of behavioral counseling for the prevention of cardiovascular disease in this population.
High-density lipoprotein cholesterol (HDL-C) is known as 'good' cholesterol, because HDL particles removes excess cholesterol from arterial walls and transport them back to the liver. A research group has developed a practical test for the ability of HDL to accept cholesterol. This method could help to prevent and monitor cardiovascular disease, and it is simple enough to be used in everyday clinical situations.
The longitudinal study on children and adolescents is unique worldwide. The study shows that cardiovascular risk factors, such as overweight, high blood pressure, low-density lipoprotein (LDL) cholesterol and insulin resistance, are associated with arterial distensibility in adolescence.
Treatment of benign prostatic hyperplasia (BPH) with the commonly prescribed Avodart (Dutsteride) may put men at an increased risk for diabetes, elevated cholesterol levels, non-alcoholic fatty liver disease (NAFLD) and worsening erectile dysfunction, new research concludes.
Scientists studying a mystery link between the dangerous pregnancy complication pre-eclampsia and an increased risk of heart disease in later life for both mother and child have uncovered important new clues.
A vaccine to immunize people against high levels of cholesterol and the narrowing of the arteries caused by build-up of fatty material (atherosclerosis) may be possible following successful results in mice. Now, a phase I trial in patients has started to see if the findings translate to humans.
Statin side effects are the strongest predictor of failure to meet low-density lipoprotein (LDL) cholesterol targets, according to new research. Other predictors were statin non-adherence and use of weaker statins.